Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Andrew Witty Stories

2014-03-18 12:31:39

LONDON, March 18, 2014 /PRNewswire/ -- UK government, leading industrial, investor and academic speakers to review strategies to support the commercialisation of academic research at a new Elsevier conference "Research Commercialisation: From Ideas to IPO": 19-20 May 2014, London, UKhttp://www.idea2ipo-conference.com With high expectations of a return on government and public investment in academic research regarding job creation and economic growth, the pressure...

GSK Stops Paying Docs To Market Meds
2013-12-18 09:15:55

Rebekah Eliason for redOrbit.com – Your Universe Online Amid accusations of bribery and scandal, GlaxoSmithKline (GSK), one of the leading drug makers, will stop paying doctors to promote its drugs and cease targets for number of prescriptions filled for the marketing staff. This is a first for the giant drug company, which has long been fighting scandals over its sales practices. Such a huge step is a major challenge to other drug companies and could force them to follow their example....

2012-07-25 02:30:47

LONDON, July 25, 2012 /PRNewswire/ -- Pharmaceutical group GlaxoSmithKline concedes pricing pressure in Europe had affected overall performance in the second quarter but says the Group was making "good progress" against its strategic agenda. In a video interview, CEO Sir Andrew Witty said he had seen strong performances in the Emerging Markets, Japan and the group's Consumer business. Looking forward he said he now expected full-year 2012 to be in line with 2011 as the...

GSK Pharma Acquires Human Genome Sciences For $3.6 Billion
2012-07-17 09:45:58

Lawrence LeBlond for redOrbit.com - Your Universe Online British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share. By securing HGS, GSK is gaining full control of the drug Benlysta, the first drug in more than 50 years to be approved by the Food and Drug Administration (FDA) for the...

Pharma Giant Agrees To Pay $3 Billion In Fines For Improper Practices
2012-07-02 19:08:05

Lawrence LeBlond for redOrbit.com - Your Universe Online Pharmaceutical giant GlaxoSmithKline (GSK) pleaded guilty and has agreed to pay the largest fine in US history over charges that it marketed drugs for unauthorized uses, held back safety data, and cheated the government´s Medicaid program, the US Justice Department (DOJ) announced Monday. GSK was also accused of paying kickbacks to doctors, funding expensive trips and other benefits, to gain their support for their drugs....

2012-07-02 06:24:57

LONDON and PHILADELPHIA, July 2, 2012 /PRNewswire/ -- GlaxoSmithKline plc (GSK) today announced that it has reached an agreement with the US Government, multiple states and the District of Columbia to conclude the Company's most significant ongoing Federal government investigations. The final settlement is a result of negotiations which reached agreement in principle in November 2011. GSK will make payments totalling $3bn which are covered by existing provisions and will be funded through...

2012-02-07 06:51:00

LONDON, February 7, 2012 /PRNewswire/ -- In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver. Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth. "This is a...

2011-07-26 07:33:00

LONDON, July 26, 2011 /PRNewswire/ -- UK pharma group GlaxoSmithKline reports a 2% sales dip in the second quarter but highlights strong underlying sales momentum. In an interview with financial broadcaster http://www.cantos.com, CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall delivery of strategy, declining "headwinds", R&D strategy, improving margins and a review of the recently implemented Drug Performance Units. The interview...

2010-10-13 18:01:00

PHILADELPHIA, Oct. 13 /PRNewswire/ -- At the launch of the World Health Organization's (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its medicine albendazole to treat children at risk of intestinal worms, known as soil-transmitted helminths (STH). Today's report confirms that intestinal worms cause more ill health in school-aged children than any other infection. STHs aggravate malnutrition and amplify rates of...

2010-02-04 07:17:00

LONDON, February 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007. In an interview on http://www.cantos.com CEO Andrew Witty also announced a reduction in the investment into treatments for pain and depression and a restructuring of R&D. He said: "Now obviously I don't like to see anybody leave the organisation or there to be any job losses. But the...